Report cover image

Global Gemcitabine Injection Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20360631

Description

Summary

According to APO Research, the global Gemcitabine Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Gemcitabine Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Gemcitabine Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Gemcitabine Injection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Gemcitabine Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Gemcitabine Injection market include Teva Pharmaceuticals, Novartis AG, Mylan Inc, Pfizer, Fresenius Kabi, Meitheal Pharmaceuticals and Accord Healthcare, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Gemcitabine Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Gemcitabine Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Gemcitabine Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gemcitabine Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gemcitabine Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gemcitabine Injection sales, projected growth trends, production technology, application and end-user industry.

Gemcitabine Injection Segment by Company

Teva Pharmaceuticals
Novartis AG
Mylan Inc
Pfizer
Fresenius Kabi
Meitheal Pharmaceuticals
Accord Healthcare
Gemcitabine Injection Segment by Type

1g/26.3 mL
200mg/5.26 mL
2g/52.6 mL
Gemcitabine Injection Segment by Application

Hospital
Clinic
Gemcitabine Injection Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Gemcitabine Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gemcitabine Injection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gemcitabine Injection significant trends, drivers, influence factors in global and regions.
6. To analyze Gemcitabine Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gemcitabine Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gemcitabine Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gemcitabine Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gemcitabine Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gemcitabine Injection industry.
Chapter 3: Detailed analysis of Gemcitabine Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gemcitabine Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gemcitabine Injection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Gemcitabine Injection Sales Value (2020-2031)
1.2.2 Global Gemcitabine Injection Sales Volume (2020-2031)
1.2.3 Global Gemcitabine Injection Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Gemcitabine Injection Market Dynamics
2.1 Gemcitabine Injection Industry Trends
2.2 Gemcitabine Injection Industry Drivers
2.3 Gemcitabine Injection Industry Opportunities and Challenges
2.4 Gemcitabine Injection Industry Restraints
3 Gemcitabine Injection Market by Company
3.1 Global Gemcitabine Injection Company Revenue Ranking in 2024
3.2 Global Gemcitabine Injection Revenue by Company (2020-2025)
3.3 Global Gemcitabine Injection Sales Volume by Company (2020-2025)
3.4 Global Gemcitabine Injection Average Price by Company (2020-2025)
3.5 Global Gemcitabine Injection Company Ranking (2023-2025)
3.6 Global Gemcitabine Injection Company Manufacturing Base and Headquarters
3.7 Global Gemcitabine Injection Company Product Type and Application
3.8 Global Gemcitabine Injection Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Gemcitabine Injection Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Gemcitabine Injection Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Gemcitabine Injection Market by Type
4.1 Gemcitabine Injection Type Introduction
4.1.1 1g/26.3 mL
4.1.2 200mg/5.26 mL
4.1.3 2g/52.6 mL
4.2 Global Gemcitabine Injection Sales Volume by Type
4.2.1 Global Gemcitabine Injection Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Gemcitabine Injection Sales Volume by Type (2020-2031)
4.2.3 Global Gemcitabine Injection Sales Volume Share by Type (2020-2031)
4.3 Global Gemcitabine Injection Sales Value by Type
4.3.1 Global Gemcitabine Injection Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Gemcitabine Injection Sales Value by Type (2020-2031)
4.3.3 Global Gemcitabine Injection Sales Value Share by Type (2020-2031)
5 Gemcitabine Injection Market by Application
5.1 Gemcitabine Injection Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Gemcitabine Injection Sales Volume by Application
5.2.1 Global Gemcitabine Injection Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Gemcitabine Injection Sales Volume by Application (2020-2031)
5.2.3 Global Gemcitabine Injection Sales Volume Share by Application (2020-2031)
5.3 Global Gemcitabine Injection Sales Value by Application
5.3.1 Global Gemcitabine Injection Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Gemcitabine Injection Sales Value by Application (2020-2031)
5.3.3 Global Gemcitabine Injection Sales Value Share by Application (2020-2031)
6 Gemcitabine Injection Regional Sales and Value Analysis
6.1 Global Gemcitabine Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Gemcitabine Injection Sales by Region (2020-2031)
6.2.1 Global Gemcitabine Injection Sales by Region: 2020-2025
6.2.2 Global Gemcitabine Injection Sales by Region (2026-2031)
6.3 Global Gemcitabine Injection Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Gemcitabine Injection Sales Value by Region (2020-2031)
6.4.1 Global Gemcitabine Injection Sales Value by Region: 2020-2025
6.4.2 Global Gemcitabine Injection Sales Value by Region (2026-2031)
6.5 Global Gemcitabine Injection Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Gemcitabine Injection Sales Value (2020-2031)
6.6.2 North America Gemcitabine Injection Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Gemcitabine Injection Sales Value (2020-2031)
6.7.2 Europe Gemcitabine Injection Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Gemcitabine Injection Sales Value (2020-2031)
6.8.2 Asia-Pacific Gemcitabine Injection Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Gemcitabine Injection Sales Value (2020-2031)
6.9.2 South America Gemcitabine Injection Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Gemcitabine Injection Sales Value (2020-2031)
6.10.2 Middle East & Africa Gemcitabine Injection Sales Value Share by Country, 2024 VS 2031
7 Gemcitabine Injection Country-level Sales and Value Analysis
7.1 Global Gemcitabine Injection Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Gemcitabine Injection Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Gemcitabine Injection Sales by Country (2020-2031)
7.3.1 Global Gemcitabine Injection Sales by Country (2020-2025)
7.3.2 Global Gemcitabine Injection Sales by Country (2026-2031)
7.4 Global Gemcitabine Injection Sales Value by Country (2020-2031)
7.4.1 Global Gemcitabine Injection Sales Value by Country (2020-2025)
7.4.2 Global Gemcitabine Injection Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.5.2 USA Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.6.2 Canada Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.8.2 Germany Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.9.2 France Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.9.3 France Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.11.2 Italy Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.12.2 Spain Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.13.2 Russia Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.16.2 China Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.16.3 China Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.17.2 Japan Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.19.2 India Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.19.3 India Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.20.2 Australia Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.24.2 Chile Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.26.2 Peru Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.28.2 Israel Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.29.2 UAE Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.31.2 Iran Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Gemcitabine Injection Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Gemcitabine Injection Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Gemcitabine Injection Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Teva Pharmaceuticals
8.1.1 Teva Pharmaceuticals Comapny Information
8.1.2 Teva Pharmaceuticals Business Overview
8.1.3 Teva Pharmaceuticals Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.1.4 Teva Pharmaceuticals Gemcitabine Injection Product Portfolio
8.1.5 Teva Pharmaceuticals Recent Developments
8.2 Novartis AG
8.2.1 Novartis AG Comapny Information
8.2.2 Novartis AG Business Overview
8.2.3 Novartis AG Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.2.4 Novartis AG Gemcitabine Injection Product Portfolio
8.2.5 Novartis AG Recent Developments
8.3 Mylan Inc
8.3.1 Mylan Inc Comapny Information
8.3.2 Mylan Inc Business Overview
8.3.3 Mylan Inc Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.3.4 Mylan Inc Gemcitabine Injection Product Portfolio
8.3.5 Mylan Inc Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.4.4 Pfizer Gemcitabine Injection Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Fresenius Kabi
8.5.1 Fresenius Kabi Comapny Information
8.5.2 Fresenius Kabi Business Overview
8.5.3 Fresenius Kabi Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.5.4 Fresenius Kabi Gemcitabine Injection Product Portfolio
8.5.5 Fresenius Kabi Recent Developments
8.6 Meitheal Pharmaceuticals
8.6.1 Meitheal Pharmaceuticals Comapny Information
8.6.2 Meitheal Pharmaceuticals Business Overview
8.6.3 Meitheal Pharmaceuticals Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.6.4 Meitheal Pharmaceuticals Gemcitabine Injection Product Portfolio
8.6.5 Meitheal Pharmaceuticals Recent Developments
8.7 Accord Healthcare
8.7.1 Accord Healthcare Comapny Information
8.7.2 Accord Healthcare Business Overview
8.7.3 Accord Healthcare Gemcitabine Injection Sales, Value and Gross Margin (2020-2025)
8.7.4 Accord Healthcare Gemcitabine Injection Product Portfolio
8.7.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Gemcitabine Injection Value Chain Analysis
9.1.1 Gemcitabine Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Gemcitabine Injection Sales Mode & Process
9.2 Gemcitabine Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Gemcitabine Injection Distributors
9.2.3 Gemcitabine Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.